Multiple law firms filed a securities fraud class-action lawsuit against ADMA Biologics, Inc. and its executives. The complaint alleges the company made false statements regarding its business practices and undisclosed related-party transactions. It specifically accuses ADMA of using channel stuffing to artificially inflate revenue growth.
A March 24, 2026, report by Culper Research triggered a significant drop in the company's stock price. The lawsuit claims these practices concealed a lack of adequate internal controls.
The class period covers investors who purchased ADMA securities between August 9, 2024, and March 25, 2026. The deadline to join as a lead plaintiff is August 10, 2026.